The genetic deletion and protein expression of PRDM1 and its clinical implications in diffuse large B cell lymphoma: A retrospective cohort study in China

Abstract

ObjectTo investigate the clinical implications of the PRDM1 deletion and PRDM1 protein expression in Chinese diffuse large B cell lymphoma (DLBCL). Materials and methodsTumor samples of 199 patients with DLBCL were obtained from the Department of Pathology of Peking University First Hospital between 2008 and 2015. The PRDM1 expression was detected by immunohistochemistry (IHC) in all samples. Among them, the PRDM1 deletion was detected in 60 samples by fluorescence in situ hybridization (FISH). The correlations between PRDM1 protein expression and PRDM1 molecular status and clinicopathological features were analyzed. ResultsImmunohistochemically, 58 (29.1%) patients were classified as the germinal center B-cell (GCB) subtype, and 141 (70.9%) patients were non-GCB subtype. PRDM1 protein was strongly expressed in 15 (7.5%) patients, weakly expressed in 67 (33.7%) patients, and negative in 117 (26.6%) patients. Heterozygous and homozygous PRDM1 deletions were observed in 28.3% (17/60) and 8.3% (5/60) of cases, respectively. The PRDM1 deletion was not significantly correlated with PRDM1 protein expression. Neither the PRDM1 protein expression nor the PRDM1 deletion was significantly associated with most clinicopathological features, including their immunophenotypes according to the Han's algorithm. However, Kaplan-Meier survival analysis showed that heterozygous and/or homozygous PRDM1 deletion but not PRDM1 expression was a poor prognostic factor in the non-GCB group. In addition, there was a positive correlation between PRDM1 and c-Myc expression. ConclusionsOur results suggested that homozygous or heterozygous PRDM1 deletion is a poor prognostic factor for non-GCB DLBCL.